Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial

• Hoofdauteurs: Shrikant Sharma (Auteur), Veer Bahadur Singh (Auteur), Sanjay Kumar (Auteur), Vipul Prajapati (Auteur), Jitendra Patel (Auteur), Rajesh Vukkala (Auteur), Sanjay Kumar Jangid (Auteur), Jayesh Sanmukhani (Auteur), Gaurav Gupta (Auteur), Pradip Patel (Auteur), Ravindra Mittal (Auteur), Reinhard Glueck (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2018-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India containing two influenza A and two influenza B...